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Background: Survival among HIV-infected patients on antiretroviral treatment (ART) has not 
been systematically evaluated in Nepal. This study explores the survival pattern and its 
determinants among adult HIV-infected patients on ART.  
Methods: This retrospective cohort study included 1024 (51.2% were men) HIV-infected 
patients aged ≥15 years who started ART between May 15, 2006 and May 15, 2011 in five ART 
centres/sub-centres in the Far-western region, Nepal. Follow-up time was calculated from the 
date of ART initiation to date of death or censoring (loss to follow-up, transferred out, or 15
th
 of 
November 2011). Mortality rates (per 100 person-years) were calculated. Kaplan-Meier and 
Cox-regression models were used to estimate survival and explore determinants of mortality.  
Results: About 12% (83% of them were male) died during follow-up. The median follow-up 
time was 19.1 months. The crude mortality rate was 6.3 (5.3-7.6); 12.2 (0.1-14.9) in male and 1.9 
(1.3-3.0) in female patients. The mortality rate was 21.9 (16.6- 28.8) within the first 3 months 
after ART initiation. The survival probability was 94.7% at 3 months and 82.9% at 5 years. The 
independent determinants of mortality were sex, baseline performance scale, baseline WHO 
clinical stage, and baseline bodyweight. Higher mortality was significantly associated with 
bedridden performance status, advanced clinical disease, low bodyweight, and change in ART 
regimen in male patients; and with active tuberculosis and low bodyweight in female patients. 
Conclusion: High mortality was observed within the first 3 months of ART initiation. Patients 
with poor clinical characteristics had higher mortality, especially male. Early initiation of ART 
should be encouraged in HIV-infected patients.   
Keywords: HIV-infected patients, antiretroviral treatment (ART), survival pattern, mortality 
rate, Far-western Development Region, Nepal. 
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1.1 Global situation of HIV/AIDS 
The Acquired Immune Deficiency Syndrome (AIDS) was first recognized among homosexual 
men in the United States in 1981. Two years later, the etiological agent, Human 
Immunodeficiency Virus (HIV) was identified [1]. Today, the infectious disease HIV/AIDS is 
one of the leading causes of death across the globe [2]. United Nations programme on HIV/AIDS 
(UNAIDS) estimated that globally there were 34 million people living with HIV at the end of 
2010 compared with 28.6 million in 2001- a 17% increase. In 2010, an estimated 2.7 million 
people became newly infected with HIV; that is 15% lower than the 3.1 million in 2001. An 
estimated 1.8 million AIDS-related deaths occurred worldwide in 2010. However, the AIDS- 
related deaths in 2010 showed a decreasing trend compared to 2.2 million deaths in 2005 [3]. 
The decline reflects the increased availability of antiretroviral therapy, as well as care and 
support to people living with HIV, particularly in low and middle-income countries. 
Nevertheless, it is also a result of a decreasing incidence starting in the late 1990s [3, 4].  
In Asia, there were 360,000 newly infected people with HIV in 2009; that is 20% lower than the 
450,000 cases in 2001 [3]. The incidence fell by more than 25% in India, Nepal, and Thailand 
between 2001 and 2009 [4]. An estimated 4.8 million people were living with HIV in 2010, 11% 
more than the 4.2 million in 2001. An estimated 310,000 AIDS-related deaths occur in Asia in 
2010 compared with 250,000 in 2001, which is the largest number of deaths outside sub-Saharan 





1.2     Global situation of Antiretroviral Treatment (ART) service 
Antiretroviral treatment is a global response to the HIV pandemic. Since the introduction of 
Zidovudine (ZDV) in 1987 as a first antiretroviral drug, there has been significant advancement 
in the antiretroviral treatment [5]. In 1995-96, the introduction of ART combination (Highly 
Active Antiretroviral Treatment – HAART) was the milestone in the history of HIV treatment 
that turns HIV infection from inevitable fatal condition into chronic manageable disease [6]. 
Today, there are six classes of antiretroviral drugs exist: Nucleoside reverse transcriptase 
inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Protease 
inhibitors (PIs), Integrase inhibitors (IIs), Fusion inhibitors (FIs), and Chemokine receptor 
antagonists (CRAs) [5]. For the treatment of people with HIV infection, the standard 
combination of ART recommended worldwide consists of three or more ART drugs [7].  
There is great improvement in ART coverage of people eligible to treatment from 7% in 2003 to 
47% in 2010 due to recent huge investment and efforts in expansion of ART programmes in low- 
and middle-income countries [3, 8]. However, by the end of 2010, about 53% of patients in need 
of ART in the low- and middle-income countries still have no access to treatment [3]. Since 
1995, the introduction of ART service has averted 2.5 million deaths in low- and middle-income 
countries, including 300,000 deaths in Asia
 
[3]. It is a well-studied and established phenomenon 
in the western world that ART reduces mortality and prevent opportunistic infection among 
HIV/AIDS patients [9]. ART programmes in resource-limited countries such as Malawi [10], 
Zambia [11], Tanzania [12], Cameron [13], Ethiopia [14], and India [15] have shown dramatic 





1.3     Country profile of Nepal 
Nepal, a landlocked country situated between china and India, occupies 147,181 square 
kilometres of area. Nepal has three distinct geographical profiles (mountain, hill, and Terai 
(plain)) [16]. Administratively, the country is divided into five development regions (Eastern 
Development Region, Central Development Region, Western Development Region, Mid-western 
Development Region, and Far-western Development Region), including 14 administrative zones, 
and 75 districts (figure 1) [17].  
 
Figure 1: Administrative and geographic map of Nepal 
 
 
Nepal is among the poorest countries in the world and currently ranks 157 out of 187 countries 
on Human Development Index (HDI) [18]. The demographic statistics of the country are 





Table 1: Nepal Demographic Statistics [19 - 23] 
Total population  26.6 million (2011, CBS) 
Population density  181 per sq. kilometres (2011, CBS) 
Population growth rate (average annual %, 2010- 2015) 1.7 (2010,  UN) 
Urban population (%) 17 (2011, CBS) 
Sex ratio (male per 100 female) 94.41 (2011, CBS) 
Life expectancy at birth (years) 67 (2010, WHO) 
Under-five mortality rate (per 1000 live births) 50 (2010, WHO) 
Adult (15- 60 years) mortality rate (per 1000 live births) 196 (2010, WHO) 
Maternal mortality ratio (per 100,000 live births) 170 (2010, WHO) 
Gross national income per capita (PPP US $) 1,210 (2010, WHO) 
Total expenditure on health per capita (US $) 66 (2010, WHO) 
Total expenditure on health as % of GDP 5.5 (2010, WHO) 
Adult literacy rate %, ≥ 15 years) 59.1 (2009, UNDP) 
 
1.4     Epidemiology of HIV/AIDS in Nepal 
Since the detection of first case in 1988, Nepal has moved from low to a concentrated epidemic 
[24]. Concentrated epidemic means HIV prevalence consistently over 5% in at least one sub-
population at highest risk, and a prevalence below 1% in the general adult population (age 15-49 
years) [25]. Over 80% of HIV infections are transmitted through heterosexual transmission. The 
key population groups at higher risk and their sexual partners are responsible for the spread of 
HIV epidemic in Nepal. The key populations with high prevalence of HIV are injecting drug 
users (IDUs), men having sex with men (MSM), female sex workers (FSWs), clients of FSWs, 
and male labour migrants to India. Among the key populations, male migrants to India and 
clients of FSWs are more responsible for fuelling the HIV epidemic because of their role of 
bridging population for transmitting HIV infection between high-risk and low-risk general 
population [24, 26-28].  
Recently, estimated 50,200 people were living with HIV and this includes 8% children aged 0-14 
years and 92% individuals aged 15 years and older. The HIV prevalence among adults (15- 49 
years) was 0.30% in 2011 [24, 36]. HIV testing and counselling was first started in Nepal in 
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1995 in Teku Hospital at National Centre for AIDS and STD Control (NCASC). The cumulative 
total HIV infections in Nepal from 1995 to July 2012 reported through regular Voluntary 
Counselling and Testing (VCT) service sites was 20,583 patients, where male, female, and 
transgender (TG) were 64%, 35.96%, and 0.04%, respectively [29, 30]. The proportionate 
distribution of population groups amongst the 43,239 estimated HIV infections aged 15-49 years 
was as follows: migrants (27%); MSWs (male sex workers), transgender and clients (7.2%); 
other MSM who do not sell/buy sex (14.4%); clients of FSWs (4.4%); IDUs (2.2%); and FSWs 
(1.5%), and the remaining male and female populations, who were classified as low-risk 
populations, accounted for 16% and 27.3%, respectively. The key high-risk populations in 2011 
accounted for 58% of all HIV infections among adults. The estimated number of HIV infections 
was highest among adults (15-49 years) male (58%) and reproductive age group (15-49 years) 
females (28%) [24, 26].  
In order to curve the tides of the epidemic, the national response to HIV/AIDS is guided by 
''National Policy on HIV and STI, 2011'' and ''National HIV/AIDS Strategy 2011- 2016'', which 
use the principle of universal access, that is, using a rights-based approach and encompassing a 
multisectoral approach. The Bilateral and multilateral agencies, private/NGOs, and government 
had jointly invested about US $ 20.45 million in HIV programmes in 2009 in Nepal. These 
efforts from policy and funding level had resulted in a marked reduction in new HIV infections 
per year (incidence) that was decreased by 31.6% in 2009 compared to 1999 [24, 28]. Although 
the new HIV infections are declining each year, it is still a great challenge to achieve the national 
HIV/AIDS strategic goals of (a) halving the number of new HIV infections by 50%, (b) reduce 
AIDS-related deaths by 25%, and (c) reduce new HIV infections among children by 90% by 
2016 [24]. There is only a slight reduction in average number of new HIV infections among 
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children (0-14 years) per year, that is, 468 in 2009 and 378 in 2011. However, the average 
number of AIDS-related deaths per year in 2009 was 4,701, whereas in 2011 it was 4,722 deaths 
[26, 31]. 
 
1.5    ART Service in Nepal 
In order to limit the evolving HIV epidemic in Nepal, the government of Nepal implements and 
rapidly expands the HIV treatment, care, and support program throughout the country. Under this 
program, free ART service (first introduced in February 2004) is delivered with the following 
goals: (a) reduction of HIV-related morbidity and mortality, (b) maximal and durable 
suppression of viral load, (c) restoration and/or preservation of immunologic function, (d) 
improvement of quality of life of HIV infected persons, (e) Prevention of Mother To Child 
Transmission (PMTCT), and (f) post Exposure Prophylaxis (PEP) [27, 32-34]. For the clinical 
management of ART there are National ART guidelines and Standard Operating Procedures in 
Nepal. In-line with the WHO/UNAIDS recommendations, National ART guidelines was first 
adopted in Nepal in 2003 and was updated in 2009 and in 2012. There are different categories of 
antiretroviral drugs used in Nepal. The standard ART regimen includes at least 3 drugs and the 
principle combinations are: (a) 2NRTI + 1NNRTI, (b) 2NRTI + PI, and (c) 2NRTI + 1NRTI 
(Abacavir). The choice of regimen for the treatment of HIV patients depends upon the cost of 
therapy; availability and affordability of drugs; convenience and likelihood of adherence; 
regimen potency, tolerability and adverse effects profile; possible drug interaction and potential 
for alternate treatment options in the event that the initial drug regimen fails. The first line ART 
regimens in adults and adolescent are ZDV/3TC/NVP, ZDV/3TC/EFV, d4T/3TC/NVP, 
d4T/3TC/EFV, TDF/3TC/NVP, and TDF/3TC/EFV. In case of treatment failure, it is 
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recommended to change to second line combination regimen. The second line regimens in adults 




 [32-34]. In Nepal, the National 
Antiretroviral Therapy Guidelines from 2003 had the following recommendations for initiating 
antiretroviral treatment in adults with documented HIV infection [32]: 
a. If CD4 Testing is available: 
- WHO Stage IV disease irrespective of CD4 cell count 
- WHO Stage I, II or III with CD4 cell counts < 200/mm3  
b. If CD4 Testing is not available: 
- WHO Stage IV disease irrespective of total Lymphocyte count 
- WHO Stage II or III disease with a total Lymphocyte count < 1200/mm3 
- WHO Stage I: Treatment is not recommended  
However, in 2009 the recommendations for initiating ART were slightly changed [32].   
a. If CD4 Testing is available: 
 -     WHO Stage III or IV disease, irrespective of CD4 cell count 
- WHO Stage I or II with CD4 cell counts < 350/mm3   
b. If CD4 Testing is not available: 
- recommended to WHO Stage III or IV disease 
- not recommended to WHO Stage I or II disease 
Since the introduction of free ART service in Nepal there have been marked improvements in the 
expansion of ART facility and service utilization. In 2009, there were 23 ART centres and by 
July 2012, the number increased to 39 ART centres in 33 districts of Nepal. CD4 count service is 
available at 16 sites, while 4 sites have CD4 calibre. ART coverage increased from 20.1% in 
2009 to 23.7% in 2011 [24, 35]. However, due to the several reasons like lack of infrastructure 
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and human resources, financial constraints like travel cost, geographical barriers, lack of 
awareness and low uptake of counselling and/or testing, limited access to services like long time 
to reach health facility, stigma, and discrimination, a majority of people are not receiving HIV 
testing service and those people who are enrolled in ART are not continuing the service [36-38]. 
Therefore, achieving the universal access target of 80% coverage of those who need ART and 
HIV/AIDS strategic goal of reducing AIDS-related death by 25% is still a big challenge [24]. 
Among people with advanced HIV infection who are currently receiving ART in Nepal, 93% 
were adults and 44.8% were females. About 0.6% of the patients currently on ART in 2012 are 
on second line regimen [35]. The outcomes of ART program by June 2012 were 77.7% alive and 
on treatment, 12.8% died, 9.8% loss to follow up, and 0.1% stopped treatment [35].  
 
1.6    Far-western Development Region, Nepal and its situation 
The Far-western Development Region is a remote and developmentally challenged region of 
Nepal, which includes nine districts. About 44% and 49% of people lives below the poverty line 
in Far-western region's Hills and Himalayan districts, respectively [39]. The projected population 
of the region is 2,629,761 (10% of total country population) in 2010 based on 2001 Census data 
[40]. Kailali and Kanchanpur districts lie in the plains, whereas Darchula, Bajura and Bajhang 
districts are mountainous and the remaining four districts (Doti, Achham, Baitadi, and 
Dadeldhura) are hilly districts [40]. HIV/AIDS data in Far-western region at the end of 2010 year 
are presented in table 2. The first HIV-infected patients registered in an ART centre after the 
initiation of ART service in Far-western region was in the 15
th
 of May 2006. 
The National Centre for AIDS and STD Control (NCASC) reported high HIV infections in the 
Far-western region of the country, where seasonal migration is more common and knowledge 




Table 2: Cumulative HIV-AIDS data in Far-western region at the end of year 2010 [40]
 
Cumulative Data Total 
Total HIV-positive including AIDS 4057 
No. of AIDS cases (out of total HIV) 1195 
No. of death due to AIDS 142 
HIV+ve treated by ART 1345 
HIV +ve receiving CPT 952 
TB among HIV+ve 104 
Opportunistic infection (OI) cases diagnosed and treated 3772 
 
About 1.5 to 2 million Nepalese has been estimated to migrate to India for seasonal and long-
term work because of limited work opportunities in Nepal and the open-border provision 
between Nepal and India. These large numbers of migrants to India mostly include HIV high-
risk labour migrants of Far-western region. About 50% - 80% of households in some 
communities of Far-western region have at least one family member working in India, and most 
of these migrants especially from Doti, Achham, Kailali, and Kanchanpur districts seasonally 
return home [39, 43, 44]. In 2001, the Nepal Population Census and Community Level Research 
carried out by CARE/ FHI 360 discovered that 27.5% of adult males in the Far-western hill 
districts were abroad for at least six months, and it has been increasing over years [28]. In the 
villages of the districts Bajhang and Bajura in Far-western region, 86% of the male and 17% of 
the female population migrates from time to time to India for labour [45]. The high proportion of 
migrants at risk to HIV in Far-western region could possibly add a new dimension to the 
epidemic and the HIV prevalence among migrants and wives of migrants in Far-western region 
shows an increasing trend [42]. Table 3 illustrates the service delivery sites of HIV/AIDS 




Table 3: Service Delivery Sites in Far-western region Nepal [40] 
Service Sites Total 
No. of STI Diagnosis and Treatment centres 61 
No. of VCT centres 25 
No. of ART centres/sub-centres 7 
No. of PMTCT centres 19 
No. of CHBC sites 6 
No. of CD4 centres 3 
No. of Blood Transfusion service centres 7 
 
 
1.7    Determinants of Survival of HIV-infected Patients on ART 
Several studies in the developed and low- and middle-income countries showed that the survival 
of HIV-infected patients on ART depends on sex, age, viral load, CD4 count, total lymphocytes, 
body mass index (BMI) or bodyweight (kg), WHO clinical stage, co-trimoxazole preventive 
therapy (CPT), haemoglobin, adherence, and nutritional support [10-15, 46-50].  
It was shown in Tanzania that men had a significantly higher risk of overall mortality and 
immunologic non-response defined as CD4 cell count <100 cells/μl after at least 6 months of 
initiating ART than women [46, 50]. Whereas, in 2010, advanced clinical stage, anaemia, and 
lack of CPT initiation were independent predictors of mortality, but not gender in Ethiopia [14]. 
With the increase in age of patients on ART increases the risk of mortality [47]. However, in 
some studies there is no significant relation between age and survival of patients on ART [14, 
50]. There is high risk of mortality among underweight patients (BMI <18.5 kg/m
2
) compared to 
patients with higher BMI [10, 13]. Some studies have revealed bodyweight in kilograms (kg). 
Lower bodyweight (kg) patients had increased risk of mortality compared to patients weighted 
more than 55 kg [50]. However, baseline bodyweight was not a significant determinant of 
mortality in Oromiyaa, Ethiopia [14]. 
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The place of residence has also significant relation with survival of HIV-infected patients on 
ART. Urban patients have higher risk of mortality in comparison to patients in rural area [50]. 
Clinical stage and baseline CD4 counts have been found as important determinants of mortality 
among HIV-infected patients on ART in lower-income countries [49]. Patients with low baseline 
CD4 counts (<50 cell/mm
3
) had higher risk of mortality compared to patients with higher CD4 
counts [11, 13, 50]. Patients in clinical stage I or II died less frequently compared to patients with 
worse clinical stages III and IV [11, 13, 14, 50]. However, in some studies, baseline CD4 count 
[14] and clinical stage [12] had no significant relation with mortality in HIV-infected patients on 
ART. Tuberculosis (TB) had positive relation with mortality of HIV-infected patients on ART in 
one study [47] while no significant relation was found in another study [11]. HIV patients on 
ART with higher haemoglobin levels had lower mortality rates [12-14], nevertheless, the use of 
CPT increases the survival of patients [14]. 
Overall, reviewing of all the determinants of mortality among HIV patients on ART in different 
studies across the globe demonstrate that important determinants differ from place to place [10-
15, 46-50]. Egger M. in 2007 reported that there are regional variations of clinical benefit of 
ART for AIDS patients in terms of mortality reduction and improved quality of life, with higher 










2. RATIONALE OF THE STUDY 
HIV/AIDS control program is one of the prioritized areas by the government of Nepal and 
strategic action plan has been developed to limit the HIV epidemic. Under treatment, care and 
support program of National centre for AIDS and STD control (NCASC), ART services rapidly 
expanded and hugely funded in order to provide free ART to the maximum number of patients 
who are in need of ART, and therefore, reduce the morbidity and mortality among HIV patients. 
Since, the introduction of ART services in Nepal there have been improvements in service 
delivery and utilization. However, a systematic research –not yet available- is needed to 
demonstrate the ART program effectiveness, justify the continued expansion and funding in 
ART program, and explain the factors contribute to enhance program effectiveness. Assessment 
of the survival patterns among HIV-infected patients who are on ART is important to determine 
the effectiveness of the ART program. Moreover, identifying significant determinants of survival 
in HIV-infected patients is necessary to target those at increased risk of death. 
 
3. PURPOSE OF THE STUDY 
3.1 General Objective: 
To assess the survival pattern and the determinants of survival among adult (≥15 years old) HIV-
infected patients on antiretroviral treatment in the Far-western Development Region, Nepal. 
3.2 Specific Objectives: 
a) To assess the survival pattern of the adult HIV-infected patients on antiretroviral treatment 
in Far-western Development Region, Nepal. 
b) To assess the determinants associated with the mortality among adult HIV-infected patients 
on antiretroviral treatment in Far-western Development Region, Nepal. 
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4. MATERIALS AND METHODS 
 
4.1 Study area 
There are seven ART centres/sub-centres in the Far-western region of Nepal. Among the seven 
ART sites, four are ART centres and three are ART sub-centres. The ART initiation to the newly 
diagnosed HIV-infected patients after HIV testing was available only in four ART centres (Seti 
Zonal Hospital, Kailali District; Mahakali Zonal Hospital, Kanchanpur District; Achham District 
Hospital, Achham District; Doti District Hospital, Doti District) and one ART sub-centre 
(Tikapur Hospital, Kailali District). The other two ART sub-centres (Baitadi District Hospital, 
Baitadi District; Bayalpata Hospital, Achham District) treat only the transferred-in HIV-positive 
patients with prior ART history who were referred from other ART centre/sub-centre within Far-
western Development Region or outside. However, HIV-infected patients with prior ART history 
were not target population for this study. Therefore, only five ART centres/sub-centres (Seti 
Zonal Hospital and Tikapur Hospital, Kailali District; Mahakali Zonal Hospital, Kanchanpur 
District; Achham District Hospital, Achham District; Doti District Hospital, Doti District) in the 
Far-western Development Region were included in the analysis. 
 
4.2 Study population and Study period 
The study population consisted of all adult HIV-infected patients (15 years of age and above) on 
ART who started the treatment between the 15
th
 of May 2006 and the 15
th
 of May 2011 at any of 
the five ART centre/sub-centres included in the study. NCASC defined children as age group of 
0-14 years [28]. Therefore, only ART taking HIV-infected patients aged ≥15 years were included 
in the study. Moreover, HIV-infected patients with previous treatment history were excluded 
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from the study. The total eligible population was 1286 adult HIV-infected patients who started 
ART between the 15
th
 of May 2006 and the 15
th
 of May 2011, and they were followed up with 
respect to death until the 15
th
 of November 2011. 
 
4.3 Study design 
A retrospective cohort study design.  
 
4.4 Data collection  
Data were collected from standard medical record registers. These registers are adopted by the 
NCASC, Ministry of Health and Population (MoHP), and were available at the ART centres/sub-
centres. There were three available registers. The first register was the Pre-ART register where 
all confirmed HIV-positive clients were registered.  Then, all the patients who started ART 
regimen were transferred to an ART register at the date of treatment initiation. The third register 
was patient’s follow-up form. For every patient, the first follow-up visit was scheduled 2 weeks 
after treatment initiation and then on a monthly basis, where medical records were updated for 
every patient during each follow-up visit. All the information (data) for this study were retrieved 
from the medical records maintained in the Pre-ART register, the ART register, and the follow-
up form at the ART centres/sub-centres. 
 
4.5 Study variables 
a) Outcome variables: 
The date of death was recorded for all HIV-infected patients, who died from all causes related to 
HIV/AIDS during the study period while on antiretroviral treatment. Patients missing their 
follow-up visits for more than 3 months were counted as loss to follow-up and the date of the last 
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registered follow-up visit was recorded as date of loss to follow-up. ART using HIV-infected 
patient, who were transferred to another ART facility, were recorded as transferred-out cases and 
their dates of transferred-out were also recorded. HIV-infected patients who were still alive and 
using the treatment on the 15
th
 of November 2011 were assessed as alive. 
b) Time variable: 
Follow-up time was calculated in months, from the date of ART initiation to the date of death or 
censoring (loss to follow-up, transferred out, or the 15
th
 of November 2011).  
c) Independent variable:  
Baseline demographic characteristics: place of ART centre/sub-centre, age, sex, and education. 
Places of ART centres were categorized into four groups according to the Districts: Kailali 
District (Seti Zonal Hospital and Tikapur Hospital), Kanchanpur District (Mahakali Zonal 
Hospital), Achham District (Achham District Hospital), and Doti District (Doti District 
Hospital). The age (in years) of HIV-infected patients on ART was recorded in the ART facility. 
Age was divided into 3 percentile groups (tertiles): 15-32 years, 33-40 years, and >40 years. Sex 
of the patients was recorded as male and female. Patients who were educated were recorded as 
literate and those who had no formal education (no primary education or more) were recorded as 
illiterate. 
Clinical characteristics:  Active TB during ART, baseline performance scale, baseline 
bodyweight, baseline WHO clinical stage, baseline CD4 count, baseline ART regimen, drug 
allergy, and baseline ART regimen change. 
HIV-infected patients having Tuberculosis (TB) during antiretroviral treatment period were 
recorded as active TB during ART. This variable includes both the HIV-infected patients on 
ART who were already on TB treatment when ART was initiated and those who started TB 
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treatment during antiretroviral treatment period. Information at the time of ART initiation was 
recorded and assessed for the variables: performance scale, bodyweight, WHO clinical stage, 
CD4 count, and ART regimen. Performance scale was categorized and recorded in three groups: 
A- normal activity, B- bedridden <50% of the day during last month, C- bedridden >50% of the 
day during last month [32-34]. Bodyweight in kilograms (kg), CD4 count in cells/mm
3
, and ART 
regimen were recorded at the ART centre/sub-centre. At the start of antiretroviral treatment, the 
clinical stage of the HIV-infected patient was assessed and recorded using the WHO clinical 
stage guidelines [Appendix 1] by the health professional at ART centre/sub centre. The WHO 
clinical stage was categorized into four groups (stage I, stage II, stage III, and stage IV), where 
stage IV is considered as the worst health condition [32-34]. The drug toxicity/side effects was 
assessed as drug allergy in this study and it was recorded as one of the reason for change of ART 
regimen and the ART regimen was changed more than one time among some HIV-infected 
patients. The change of baseline ART regimen was recorded and assessed as binary variable.  
 
4.6 Data Analysis 
Adult HIV-infected patients who had no follow-up visits and in addition, patients without date of 
ART initiation and date of occurrence of events (i.e. death, loss to follow up, and transferred out) 
were excluded from study (n= 221). An additional 41 patients were excluded due to invalid 
follow-up information on at least one follow-up visit (for example, transferred out date earlier 
than first follow-up visit date). Thus, 1024 adult HIV-infected patients were used in analysis out 
of 1286 adult HIV-infected patients taking ART between 15 May 2006 and 15 May 2011 in Far-
western Development Region, Nepal (Figure 2). 
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Data collected from ART centres/sub-centres were entered in SPSS datasheet and were re-
checked to minimize the errors in data entry. Data were analysed using the statistical software 
STATA and SPSS. Mortality rates (per 100 person-years at risk) and survival probabilities 
(percentage) across various time intervals were assessed using STATA 12.0 (StataCorp. 2011. 
Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). The rest of the 
analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL., USA). 
Independent-sample T-test (for continuous variables) and Chi-square test (for categorical 
variables) were used to explore significant difference in patient's characteristics between males 
and females HIV-infected patients. Kaplan-Meier (KM) models were used to estimate survival 
probability after ART initiation. Log rank tests were used to compare survival curves among the 
categories of each variable. All the baseline demographic and clinical characteristics were used 
as independent variables in the analysis. Very few individuals were taking TDF/3TC/EFV 
regimen. So, this regimen was not used in Kaplan-Meier models and Cox-regression models to 
prevent power problems. Proportional hazard assumption was assessed separately for all the 
independent variables. The graphical method was used, where the log minus log KM-curves 
indicated that all the independent variables satisfied the proportional hazard assumption. The 
Cox-proportional hazard model was used to assess the relationship between the independent 
variables and mortality, where Hazard Ratio (HR) indicate the strength of the relationship. The 
univariate Cox-regression analysis was used to estimate the unadjusted Hazard Ratios (HRs), and 
the stepwise (backward LR) multivariate Cox-regression analysis was performed to estimate the 
adjusted hazard ratios. The probability for the stepwise regression was 0.05 for entry of the 
variables and 0.10 for removal of the variables. All the tests were two-sided and the criterion for 
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statistical significance was p<0.05. Wald statistics was used to explain the strongest determinants 
of mortality. 
The Cox-regression analysis was performed in three steps: a) first, the univariate and 
multivariate analysis (including all independent variables) was done to explore significant 
determinants of mortality among adult HIV-infected patients on ART.  b) secondly, all the 
statistically significant variables in the multivariate analysis in the first step along with age 
(continuous variable) were included in the multivariate model stratified by the different age 
groups (15-32 years, 33-40 years, and >40 years). c) lastly, to assess the significant determinants 
of mortality among male and female separately, the univariate and multivariate analyses 
(including all independent variables) was stratified by sex.  
 










HIV-infected patients on ART  
(15 May 2006 – 15 May 2011),  
5 ART centers/sub-centers 
1286 adult HIV-infected 
patients on ART 
120 children <15 years. 
548 patients with prior ART history. 
1024 adult HIV-infected 
patients on ART were included 
in the analysis 
25 with no follow up visit. 
196 with incomplete records. 
41 with invalid information on at 
least one follow up visit. 
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5. ETHICAL CONSIDERATION 
Ethical clearance of this study was approved from Nepal Health Research Council [Appendix 4] 
and National Centre AIDS and STD Control (NCASC), Nepal [Appendix 5]. Letter of 
Permission for data collection was obtained from all the seven ART centres/sub-centres in Far-
western Development Region, Nepal [Appendix 6 – 12].  
During data collection, only the principle researcher had access to the medical record registers 
used in the ART centres, which include participant's identity. However, all the data collected in 
the questionnaire forms [Appendix 2] were registered with a consecutive participant's number. 








During the study period (May 15, 2006 to May 15, 2011), a total of 1954 HIV-infected patients 
were on antiretroviral treatment (ART) in the 5 ART centres/sub-centres of Far-western 
Development Region, Nepal. Finally, after excluding all the non-eligible HIV-infected patients 
for this study, 1024 adult HIV-infected patients were included. 
Baseline demographic and clinical characteristics 
In Figure 3, the histogram shows the age distribution of the HIV-infected patients on ART, and 
the normal curve shows an asymmetrical distribution of age.  The median age of the patients at 
start of antiretroviral treatment was 35 years, and the age ranged from 15 to 72 years with an 
Interquartile range of 30-42 years. Most of the patients (39.2%) were in age group 33-40 years. 
However, most of the deaths (14.4%) occurred among the patients in age group >40 years 
(27.8%) and proportion of deaths was 8.0% among 33.0% of patients aged 15-32 years (Table 4). 
Mean age at start of treatment among sexes significantly differs (p value <0.001). 




The baseline demographic and clinical characteristics of adult HIV-infected patients on 
antiretroviral treatment are summarized in Table 4. Male patients constitute 51.2% of the total 
sample size and the proportion of deaths among male was 18.9% and 4.2% among female. Most 
of the adult HIV-infected patients were illiterate (73.5%). However, deaths proportion among 
literate was 15.0% and 10.6% among illiterate. About 1 out of 11 patients had >50% bedridden 
performance status, and the proportion of death among those patients was 32.2%. There was 
significant differences in performance status between male and female patients (p value <0.001). 
The median baseline bodyweight was 45 kg (Interquartile range 40-50). There was statistically 
significant difference in mean baseline bodyweight between male and female patients (p value 
<0.001). Almost half (49.1%) of patients on treatment were less than 45 kg and proportion of 
deaths was 12.0%. The least number of patients (17.2%) were of WHO clinical stage IV, where 
proportion of deaths was 25.5%. There was significant differences in baseline WHO clinical 
stage between male and female patients (p value <0.001). Among HIV-infected patients on 
treatment, the median baseline CD4 count was 149 cells/mm
3
 (Interquartile range was 80-210). 
Fewer patients (13.6%) had baseline CD4 count of 50 or less cells/mm
3
 and the proportion of 
death among them was 15%. Difference in mean baseline CD4 count was statistically significant 
between sexes (p value <0.001). About 1 in 5 patients had drug allergy and about 16.7% of those 
with drug allergy died during follow-up. Although, few patients (16.4%) had active TB during 
treatment, the proportion of death among HIV-infected patients with TB was 18.5%. The active 
TB status differs significantly between male and female patients (p value <0.001). Most of the 
adult HIV-infected patients were recommended ZDV/3TC/NVP regimen (69.0%) and the 
TDF/3TC/EFV regimen (0.3%) was rarely recommended at initiation of treatment. About 1 in 4 
patients were recommended to change baseline ART regimen. The proportion of deaths among 
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patients with baseline ART regimen change was 16.0%, while 10.3% of the patients with no 
baseline ART regimen change died. More than half (57.6%) of the patients were treated at the 
Seti Zonal Hospital, Kailali District. Among patients in Kanchanpur Zonal Hospital and Doti 
District Hospital, the proportion of deaths were 18.6% and 18.2%, respectively. 
 
Table 4: Baseline demographic and clinical characteristics of 1024 patients on ART  
Characteristics Number of patients (%)
a 






500 (48.8 %) 
524 (51.2 %) 
 
21 (4.2 %) 
99 (18.9 %) 
Age (years) 
15- 32 years 
33- 40 years 
>40 years 
 
338 (33.0 %) 
401 (39.2 %) 
285 (27.8 %) 
 
27 (8.0 %) 
52 (13.0 %) 






650 (73.5 %) 
234 (26.5 %) 
140 (13.6 %) 
 
69 (10.6 %) 
35 (15.0 %) 






732 (73.1 %) 
182 (18.2 %) 
87 (8.7 %) 
23 (2.2 %) 
 
45 (6.1 %) 
44 (24.2 %) 
28 (32.2 %) 
Baseline Bodyweight (kg) 
< 45 Kg 




484 (49.1 %) 
479 (48.6 %) 
23 (2.3 %) 
38 (3.7 %) 
 
58 (12.0 %) 
49 (10.2 %) 
2 (8.7 %) 
Baseline WHO Clinical stage 
Stage I or II  
Stage III  
Stage IV  
Missing data 
 
320 (34.2 %) 
455 (48.6 %) 
161 (17.2 %) 
88 (8.6 %) 
 
10 (3.1 %) 
63 (13.8 %) 
41 (25.5 %) 











127 (13.6 %) 
533 (57.1 %) 
274 (29.3 %) 
90 (8.8 %) 
 
19 (15.0 %) 
69 (13.0 %) 
14 (5.1 %) 




Table 4 continued   
Characteristics Number of patients (%)
a 







788 (80.9 %) 
186 (19.1 %) 
50 (4.9 %) 
 
83 (10.5 %) 
31 (16.7 %) 




856 (83.6 %) 
168 (16.4 %) 
 
89 (10.4 %) 











151 (14.8 %) 
44 (4.3 %) 
702 (69.0 %) 
118 (11.6 %) 
3 (0.3 %) 
6 (0.6 %) 
 
26 (17.2 %) 
7 (16.0 %) 
64 (9.1 %) 
20 (17.0 %) 
0 




760 (74.2 %) 
264 (25.8 %) 
 
78 (10.3 %) 
42 (16.0 %) 
ART centre/sub centre 
Seti Zonal Hospital 
Kanchanpur Zonal Hospital 
Achham District Hospital 
Doti District Hospital 
Tikapur Hospital 
 
590 (57.6 %) 
70 (6.8 %) 
176 (17.2 %) 
176 (17.2 %) 
12 (1.2 %) 
 
51 (8.6 %) 
13 (18.6 %) 
24 (13.6 %) 
32 (18.2 %) 
0 
a
 column percentage (missing data was excluded from the calculations of non-missing data percentages);  
b
 row percentage;  
#
 all regimen were first line ART regimen.  
Note: missing data refers to incomplete/missing recorded characteristics of some patients.  
 
Survival analysis 
Among 1024 adult HIV-infected patients, 14 (1.4%) were lost to follow-up, 199 (19.4%) were 
transferred-out to other ART centre/sub-centre within Far-western Development Region or 
outside the region, 120 (11.7%) died, and 691 (67.5%) were still alive by the 15
th
 of November 
2011 (Figure 4). Among 120 patients who died, 51 (42.5%) died within 3 months after start of 
treatment. There was inadequate information regarding the causes of deaths among adult HIV-
infected patients on antiretroviral treatment.  
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Figure 4: Study outcomes with percentage distribution among 1024 patients on ART. 
 
The median follow-up time of all the patients was 19.1 months or 1.59 years (Interquartile range 
0.57 – 2.93 years). The study cohort had contributed a total of 1895 person-years of follow-up. 
Over the study period, the total mortality rate was 6.33 per 100 person-years at risk. However, 
mortality rate was 21.89 per 100 person-years in the first 3 months after ART initiation. In male 
cohort, the mortality rate was about 12 per 100 person-years, while in the female cohort the 
mortality rate was about 2 per 100 person-years over the study period (Table 5). Figure 5 
illustrates how the mortality rates among male and female HIV-infected patients decreases over 
follow-up time.  





Mortality rate per 100 person-years at risk (95% CI) 
Female (N=500) Male (N=524) Both (N=1024) 
0 – 3 months 6.84 (3.42 – 13.69) 37.02 (27.46 – 49.92) 21.89 (16.63 - 28.80) 
0 – 6 months 5.32 (3.02 – 9.36) 31.63 (24.94 – 40.12) 18.15 (14.58 - 22.60) 
0 – 1 year 3.36 (1.99 – 5.67) 21.36 (17.15 – 26.59) 11.88 (9.71 - 14.54) 
0 – 2 years 2.47 (1.56 – 3.93) 15.88 (12.99 – 19.42) 8.52 (7.09 - 10.25) 
0 – 5 years 1.94 (1.26 – 2.97) 12.25 (10.06 – 14.91) 6.34 (5.30 - 7.58) 
Over the study period 1.93 (1.26 – 2.97) 12.23 (10.05 – 14.90) 6.33 (5.29 - 7.57) 
N= total number of patients 
 
 


























Figure 5: Mortality rates (per 100 person-years) among male and female HIV-infected patients 













The study shows a decreasing trend of survival probability among adult HIV-infected patients 
over follow-up time (Figure 6). The survival probability of patients at 3 month, 6 month, 1 year, 
2 year, and at 5 year was 94.66% (95% CI: 93.03%- 95.91%), 91.43% (95% CI: 89.44%- 
93.06%), 89.65% (95% CI: 87.47%- 91.47%), 86.53% (95% CI: 83.96%- 88.72%), and 82.86% 






Figure 6: Kaplan-Meier survival curve of adult HIV-infected patients on ART 
 
  
Figure 7 shows the survival probability of HIV-infected patients on ART according to different 
baseline demographic and clinical characteristics. The survival probability differs significantly 
between male and female (p value <0.001).  
There was statistically significant difference in patient's survival probability among different 
groups of age (p value 0.023), places of ART centre/sub-centre (p value 0.007), baseline 
performance scales (p value <0.001), baseline WHO clinical stages (p value <0.001), baseline 
CD4 count (p value <0.001), baseline ART regimens (p value 0.003), and active TB during 




Figure 7: Survival probabilities of HIV-infected patients on ART according to different baseline 


























Table 6 summarizes the results of the univariate and stepwise (backward LR) multivariate 
analysis of the association between the possible determinants of mortality and risk of death. In 
univariate analysis, place of ART centre/sub-centre, sex, age, baseline performance scale, 
baseline bodyweight, baseline WHO clinical stage, baseline CD4 count, active TB during 
treatment, and baseline ART regimen had statistically significant relation with the mortality in 
adult HIV-infected patients. However, in the multivariate analysis, only sex, performance scale, 
bodyweight, and WHO clinical stage were found as significant determinants of mortality. The 
risk of death increased 4.55-fold (95% CI: 2.43- 8.51) in male compared to female patients. 
Patients with baseline performance scale of bedridden <50% were 2.05 times more likely to die 
compared to the patients with normal performance scale at start of treatment (HR 2.05; 95% CI: 
1.19- 3.52). However, the risk of mortality increased to 3.41 times when the patients had baseline 
performance scale of bedridden >50% compared to patients with normal baseline performance 
scale (HR 3.41; 95% CI: 1.67- 6.98). The baseline bodyweight had protective effects on 
mortality of patients. For each kilogram increase in baseline bodyweight, the risk of mortality 
decreased by 4% (HR 0.96; 95% CI: 0.93- 0.99). HIV-infected patients with WHO clinical stage 
III had 2.96-fold increased risk of death compared to patients with stage I or II (HR 2.96; 95% 
CI: 1.31- 6.69). However, the risk of death among WHO clinical stage IV patients was even 
higher- compared to stage I or II patients (HR 3.28; 95% CI: 1.30- 8.29).  
Categorizing baseline CD4 count (into three groups: ≤50 cells/mm
3





) and place of ART centre/sub-centre (into two groups: Hill region (Doti District 
and Achham District) and Plain/Terai region (Kailali District and Kanchanpur District)) showed 




Table 6: Hazard ratios (HR) of mortality in 1024 patients on ART 
 
Determinants Univariate analysis Multivariate analysis 
HR (95% CI) P value HR (95% CI) P value 
Place of ART  # 






2.03 (1.10- 3.73) 
1.93 (1.24- 3.00) 






















Age groups (years) 
15- 32 years (ref.) 




1.66 (1.04- 2.64) 






















4.54 (2.99- 6.88) 







2.05 (1.19- 3.52) 





Bodyweight (Kg)* 0.98 (0.95- 0.99) 0.048 0.96 (0.93- 0.99) 0.010 
WHO clinical stage 













2.96 (1.31- 6.69) 





































0.90 (0.39- 2.07) 
0.49 (0.31- 0.77) 


















 Kailali District (Seti Zonal Hospital and Tikapur Hospital), Kanchanpur District (Kanchanpur Zonal Hospital), 
Doti District (Doti District Hospital), and Achham District (Achham District Hospital).  
*
 Continuous variables. 
ǂ
 ART regimen TDF/3TC/EFV was not included.  
(ref.) reference group.  
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Table 7 summarizes the stepwise (backward LR) multivariate results in the age groups: 15-32 
years, 33-40 years, and >40 years, separately. In 15-32 years old patients, baseline WHO clinical 
stage and sex were significantly associated with mortality. However, among 33-40 years patients 
sex, baseline performance scale, and baseline bodyweight were independent predictor of 
mortality. Among >40 years patients baseline performance scale and sex had significant 
association with mortality of adult HIV patients. 
 




15- 32 years 
(N=338) 










4.94 (1.81- 13.44) 
 
1.00 
7.21 (3.22- 16.11) 
 
1.00 
6.60 (2.02- 21.61) 
    
Age (years)* 1.20 (0.94- 1.28) 1.02 (0.91- 1.16) 1.02 (0.98- 1.07) 







0.95 (0.30- 2.97) 
2.46 (0.69- 8.76) 
 
1.00 
2.99 (1.55- 5.80) 
3.32 (1.44- 7.63) 
 
1.00 
4.26 (1.97- 9.20) 
6.70 (2.69- 16.69) 
    
Bodyweight (kg)* 0.95 (0.89- 1.01) 0.94 (0.90- 0.99) 0.98 (0.93- 1.04) 
    
WHO clinical stage 
Stage I or II (ref.) 
Stage III  
Stage IV  
 
1.00 
4.25 (0.94- 19.13) 
9.16 (1.95- 42.93) 
 
1.00 
1.55 (0.58- 4.19) 
1.49 (0.44- 5.01) 
 
1.00 
2.85 (0.63- 12.97) 
2.91 (0.58- 14.71) 
*
 Continuous variables, (ref.) reference group, N=total patients 
HRs for non-significant variables (with all non-significant subcategories) were reported from the first iteration point 
in stepwise (backward LR) Cox-regression multivariate model. 
 
Among patients aged 15-32 years, the risk of mortality was about 5 times higher in male 
compared to female (HR 4.94; 95% CI: 1.81- 13.44). Patients in clinical stage IV had 9-fold 
increased risk of death compared to clinical stage I or II patients (HR 9.16; 95% CI: 1.95- 42.93). 
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Among patients aged 33- 40 years, male patients had about 7-fold increased risk of death 
compared to female (HR 7.21; 95% CI: 3.22- 16.11). In comparison to normal performance 
status patients, increased risk of death was found in patients who were bedridden <50% (HR 
2.99; 95% CI: 1.55- 5.80) and bedridden >50% (HR 3.32; 95% CI: 1.44- 7.63). For each 1 kg 
increase in baseline bodyweight, the risk of mortality decreased by 6% (HR 0.94; 95% CI: 0.90- 
0.99). Among patients aged >40 years, male patients had 6.6-fold increased risk of death 
compared to female (HR 6.60; 95% CI: 2.02- 21.61). The patients who were bedridden <50% 
and >50% of the day had HRs of 4.26 (95% CI: 1.97- 9.20) and 6.70 (95% CI: 2.69- 16.69) 
compared to the normal performance level patients on ART.  
 
In the multivariate analysis in Table 6, the Wald statistics showed that sex was the strongest 
determinant of mortality among adult HIV-infected patients. Nonetheless, the mortality rates 
among male and female were remarkably different, also significant difference of baseline WHO 
clinical stages, baseline performance scales, mean baseline CD4 count, and mean baseline 
bodyweight between male and female were observed. Thus based on the above evidence and 
having large a number of male (524) and female (500) populations in study, the determinants of 
mortality were assessed separately for male cohort and female cohort. 
Table 8 summarizes the univariate and stepwise (backward LR) multivariate results stratified by 
sex. Among female patients, active TB during treatment and baseline bodyweight were 
significantly associated with mortality in multivariate analysis. However, among male patients 
the baseline bodyweight, baseline performance scale, baseline WHO clinical stage, and change 








Female (N=500) Male (N=524) 
Univariate 
HR (95% CI) 
Multivariate 
HR (95% CI) 
Univariate 
HR (95% CI) 
Multivariate 
HR (95% CI) 
Place of ART 
#
 



















15- 32 years (ref.) 














































 0.85 (0.77-0.93) 0.87 (0.80-0.96) 0.94 (0.92-0.97) 0.96 (0.93-0.99) 
WHO clinical stage 
Stage I or II (ref.) 
Stage III  
Stage IV  
 
1.00 


























































































Kailali District (Seti Zonal Hospital and Tikapur Hospital), Kanchanpur District (Kanchanpur Zonal Hospital), 




ART regimen TDF/3TC/EFV was not included.  
(ref.) reference group, N=total patients,
 **
 There was no death on d4T/3TC/EFV regimen group.  
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In female patients, the risk of mortality decreased by 13% for every 1 kg increase of baseline 
bodyweight (HR 0.87; 95% CI: 0.80- 0.96). Female patients with active TB during treatment had 
4.15-fold increased risk of death compared to female patients without active TB during treatment 
(HR 4.15; 95% CI: 1.36- 12.63).  
Compared to normal male patients, male patients with performance scale of bedridden <50% and 
those bedridden >50% had about 2-fold and 3-fold increased risk of death: (HR 1.97; 95% CI: 
1.20- 3.55), (HR 3.21; 95% CI: 1.45- 7.10), respectively. Mortality decreased by 4%, if 
bodyweight increased with 1 kg among male patients (HR 0.96; 95% CI: 0.93- 0.99). Male 
patients with clinical stage III had 3.64-fold increased risk of death (HR 3.64; 95% CI: 1.29- 
10.30) and those with clinical stage IV had 3.47-fold increased risk of death (HR 3.47; 95% CI: 
1.11- 10.79) compared to male patients with clinical stage I or II. Male patients who did changed 
the baseline ART regimen had 75% increased risk of death compared to patients who did not 










Over the study period, the mortality rate was 6.33 per 100 person-years, where mortality rate in 
first 3 months after ART initiation was about 22 per 100 person-years. The survival probability 
was 94.7% at 3 months and 82.9% at 5 years. The major independent determinants of mortality 
among adult HIV-infected patients on ART were male sex, poor baseline performance scale, low 
baseline bodyweight, and poor baseline WHO clinical stage.  
To my knowledge, this study is the first systematic research to assess the survival and its 
determinants among adult HIV-infected patients on ART in Nepal. In this 5-year retrospective 
cohort study, 11.7% of the adult HIV-infected patients on ART died that was similar with the 
overall deaths (11.8%) on ART program in Nepal by July 2011 [51].  
The causes of deaths were not investigated in this study; however, it is well known that 
opportunistic infections (OIs) are the major causes of mortality among HIV/AIDS patients. In 
Nepal, the most prevalent OIs among HIV/AIDS patients are Tuberculosis (TB), Candidiasis and 
Cryptosporidiosis [52, 53]. The overall mortality rate (per 100 person-years) in this study is quite 
higher than in Switzerland (0.78) [54], but it is in line with the rate in Ethiopia (7.0), although the 
adult HIV prevalence (1.5%) in Oromiyaa, Ethiopia [55] was higher than Nepal (0.30%) [25, 
26]. There was higher mortality rate among male in comparison to female over the study period, 
which is similar with other studies [11, 50]. Similar with other studies, the first 3 months 
mortality after ART initiation was highest [11, 12]. The poor outcome in the first few months 
after ART initiation might be explained by the fact that 70.7% patients had advanced disease 
(CD4 count ≤200 cells/mm
3
) and 65.7% patients had advanced clinical symptoms (WHO clinical 
stage III or IV) at the time of treatment initiation. Some factors like lack of prior access to ART 
service, stigma and discrimination related to HIV/AIDS, and limited availability of quality 
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Voluntary Counselling and Testing (VCT) services in most areas might have played role in 
delayed diagnosis. Lack of diagnostic facility and proper screening of OIs, and limited 
availability of prophylaxis might also have increased the mortality [14, 36-38]. A study in 
Ethiopia observed that advanced clinical stage (stage IV) was strongly associated with high 
mortality during the first months of treatment [56].  
Among loss to follow-up patients, median baseline CD4 count was 101.5/mm
3
 that was very 
close with death cases (104.5/mm
3
), and was highly different from survivors (160/mm
3
). 
Similarly, about 76.9% lost to follow-up patients were in WHO clinical stage III/IV that was 
quite high in comparison to survivors (60.4%). In addition, the median follow-up time of death 
(3.6 months) and lost to follow-up patients (13.2 months) was quite lower than median follow-up 
time of survivors (29.4 months). Based on the above evidence, lost to follow-up patients might 
be more at risk of death, Therefore, a worst-cases-scenario analysis was performed assuming all 
lost to follow-up patients were dead immediately after the last date of contact. In that analysis, 
the mortality rate over the study period was estimated at 7.1 per 100 person-years at risk. 
 
Determinants of Mortality 
The variations in the mortality rates indicate that ART is not the only factor that reduces the 
mortality and increases the survival among HIV/AIDS patients, but this could depend on the 
adherence, quality of service, and characteristics of patients [9, 13].  In this study, the 
independent determinants of mortality vary among different age groups of patients and among 
male and female patients on treatment. To my knowledge, determinants of mortality had never 
been examined separately for age groups and sexes of the HIV-infected patients. Although, the 
results of new analyses showed a wider confidence limits (i.e. might indicate a power problem) it 
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highlights the need of larger studies to explore the differences of the determinants of mortality 
between age groups and sexes of the patients. 
Sex:  
In Nepal, male HIV-infected patients reported through VCT by July 2012 were double than 
female [30]. However, the proportion of male ART receiver was 10% more than female in Nepal 
[35]. This indicates that female patients tend to enrol more frequently in ART service than male, 
which might be due to the linkage between the prevention of mother-to-child transmission 
(PMTCT) and treatment and care program [57].  
The higher risk of mortality among male adult HIV-infected patients in this study is similar to 
several [10, 11, 13, 46, 50], but not all previous studies [12, 14], where the latter showed no 
significant relationship between sex and mortality. This might be due to differences between 
studies in term of sample size, follow-up time, and study setting.  
The mortality was higher in male than female in all age groups of the HIV-infected patients. The 
poor baseline performance status (bedridden <50% and bedridden >50% of the days in last 
month), lower baseline bodyweight, advanced clinical diseases (stage III or IV), and change in 
baseline ART regimen had significant role for higher mortality among male HIV-infected 
patients. This implies that male patients died mostly because of their late initiation of ART when 
they had the worst health condition. In Far-western region, the HIV prevalence among male 
labour migrants is high. These migrants are usually economic pillars of their house and most of 
the time of the year they stay outside their homes, mainly in India for work [41, 42].  Late 
reporting to treatment centre unless experiencing worst HIV/AIDS related symptoms, and poor 
adherence among male might be more prevalent. Nevertheless, stigma and discrimination, and 
economic responsibility might hinder them to come forward for early testing and treatment. 
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Although, this study found that TB (opportunistic infection) and low bodyweight (poor 
nutritional status) were significantly associated with death among female patients, the important 
variables indicating late reporting to ART centres; baseline CD4 count, baseline WHO clinical 
stage, and baseline performance scale, had no significant risk of mortality among female HIV-
infected patients. Female patients would have early initiation of treatment in Far-western region, 
as female migration to work in India is rare. Therefore, they are mostly in coverage of the rapidly 
expanding HIV/AIDS prevention, treatment, care and support program in Nepal. Moreover, 
community based PMTCT program might effectively encouraged females to get to know their 
HIV status and start early treatment through awareness and counselling services.  
Age:  
Mortality did not significantly differ with age of HIV-infected patients on ART and this finding 
is consistent with the findings of studies in lower-income countries [49, 10, 50]. However, some 
studies had contrast finding, where a study in California, USA found higher death rate in older 
HIV/AIDS patients (aged >40 years) compared to younger patients [58] and  another study in 
Portugal found significant association between age of the HIV-infected patients and mortality 
[47]. The different effect of age on mortality between countries might be due to the 
methodological differences between studies and/or differences in age distribution, different 
lifestyle, personal health care, health service utilization and adherence to ART in different age 
groups between different countries.  
Baseline bodyweight:  
The inverse association between baseline bodyweight and mortality shown in this study is 
similar to several other studies, where low bodyweight or body mass index (BMI) was 
significantly associated with higher mortality [10-13, 50]. In this study, bodyweight was assessed 
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in kilogram (kg) rather than using the composite variable body mass index (BMI) because of the 
limited information on height of the patients. Although, lower bodyweight is a proxy indicator of 
advanced disease (low CD4 and worst clinical stage) and risk factor of opportunistic infections 
like TB [50, 59]. The independent significant association of low bodyweight with mortality 
shown in this study could indicate that malnutrition, poor immunity, and poor living standards, 
which are associated with low bodyweight, are also responsible for the increased risk of 
mortality. 
Baseline performance scale and WHO clinical stage: 
Adult HIV-infected patients who were bedridden for <50% or >50% of the days during last 
month had higher risk of mortality compared to the patients with normal baseline performance 
status at treatment initiation. A study in Ethiopia showed similar findings, where bedridden 
performance status (not able to perform activities of daily living) was significantly associated 
with mortality [60]. Another study in Ethiopia found no significant association, but when lost to 
follow-up patients were counted as death cases significant association was found [55].  
Patients with advanced clinical diseases (WHO stage III or IV) had higher mortality compared to 
patients with WHO stage I or II. This finding was supported by several other studies done in 
Tanzania [50], Zambia [11], Ethiopia [14], Cameroon [13], and in low-income countries [49]. A 
contrast result was found in a study done in a rural hospital in Tanzania, where clinical stage IV 
was not found significantly associated with mortality among adult HIV-infected patients 
compared to clinical stage I-III [12] and this might be due to the different study setting, follow-





This study highlights that beside sex, advanced clinical disease (WHO clinical stage III or IV) is 
the main determinant of high mortality among patients of aged 15-32 years, , while bedridden 
baseline performance status is the main determinant among patients aged >32 years .  
Active TB during treatment: 
Active TB was an independent predictor of mortality among female HIV-infected patients. A 
study done among HIV-infected patients in Portugal is consistent with our finding, where the TB 
was significantly associated with mortality [47]. A contrast finding was found in two studies 
done among HIV-infected patients in Tanzania [61] and Zambia [11], where the TB had no 
significant relationship with mortality; however, these studies included both male and female 
patients as one group.   
Change in baseline ART regimen: 
The change in baseline ART regimen had significant association with mortality among male but 
not female HIV-infected patients. A comparative study done in urban Tanzania found no 
significant sex-related difference in ART change within first-line regimens and mortality [46]. 
Drug toxicity, TB, and pregnancy are the common reasons for change in baseline ART regimen 
[62, 63]. However, the insignificant association between TB and mortality in male patients 
would not explain the increased mortality in those who changed baseline ART regimen. Larger 
studies are needed to prove change in baseline ART regimen as an independent predictor of 
mortality among male HIV-infected patients. 
Baseline CD4 count: 
The baseline CD4 count was not significantly associated with mortality in this study and this 
finding is consistent with the study done in Ethiopia [14]. However, most of the studies had 
contrast finding, where mortality varied significantly with baseline line CD4 count among HIV-
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infected patients. A study done in Cameroon [13] showed that patients with CD4 count ≤50 had 
1.85 times higher mortality compared to >50 CD4 count. A study done in Tanzania [50] found 
higher mortality among patients with CD4 count <50 or 50-199 compared to >200 CD4 count. A 
study done in low-income countries [49] found that HIV-infected patients with CD4 count less 
than 25 died 3.34 times more than patients with  ≥50 CD4 count. In the present study most of the 
patients (86.4%) had CD4 count of >50 cells/mm
3
, which could have made the comparison with 
higher CD4 count statistically unstable. However, examining CD4 count as continuous variable 
did not show a significant association.  
 
Strengths and limitations 
There are some limitations of this study. There was –relatively few- incomplete information on 
date of ART initiation, loss to follow-up, transferred out, and deaths; and invalid information on 
at least one follow-up visits among study eligible patients in study areas. The exclusion of these 
patients (18.43% of study eligible patients) from our study analysis might have worsened the 
better cohort retention. Moreover, although the proportion of loss to follow-up patients was low 
(1.4%) compared to other low- and middle-income countries, that is, Tanzania (9.7%) [12], 
Zambia (21%) [11], the outcome of loss to follow-up patients was unknown and most probably 
the loss to follow-up patients might include individuals who died at home without being 
reported. However, in the worst-cases-scenario analysis (assuming all lost to follow-up patients 
were dead immediately after the last date of contact), the same determinants of mortality found 
in the present study kept their significant association with increased mortality. Previous studies 
had found haemoglobin level [11-14] and ART adherence [11] as important determinants of 
mortality among HIV-infected patients on ART. However, this study was unable to analyze the 
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role of these variables on mortality due to the - relatively high - incomplete/missing data. 
Nevertheless, this study was unable to explore the exact causes of death and related them to all to 
HIV due to lack of relevant information.  
The main strength of this study is the large sample size, where all the eligible HIV-infected 
patients in Far-western development region, Nepal were included. The follow-up time was long 
enough to estimate survival and it determinants. Sample size was relatively large to perform a 
stratified analysis by age and sex, to show at least any trends of differences in the determinants 
of mortality so they could be analysed in the larger studies in the future. This study used the 
routine treatment program data, which is cost effective and the findings would probably give a 
crucial insight to develop an effective and efficient HIV/AIDS treatment, care, and support 




Over the study period, mortality rate among male was about 6-fold higher than female HIV-
infected patients. Majority of deaths were observed within 3 months of ART initiation and the 
difference in mortality between male and female was persistent over time. There was decreasing 
trend of survival probability over time. Higher mortality among adult HIV-infected patients was 
associated with male patients and poor baseline clinical characteristics: bedridden baseline 
performance status, lower baseline bodyweight, advanced baseline clinical disease (WHO 





9. RECOMMENDATIONS & FURTHER RESEARCH 
a) Early initiation of ART needs to be encouraged among HIV-infected patients, especially 
male patients. The ART centres need to establish and rapidly expand awareness and 
counselling program to facilitate and motivate HIV-infected patients for treatment service 
utilization. 
b) HIV Voluntary Counselling and Testing (VCT) centre need to be expanded and 
strengthened, and peoples (mainly male labour migrants in Far-western region) should be 
encouraged to come forward for early HIV testing.  
c) Prompt diagnosis and management of opportunistic infection (mainly TB) should be done 
among HIV-infected patients.  
d) The nutritional support program should be strengthened and HIV-infected patients need 
to be given proper counselling on nutritional feeding. 
e)  Causal reasons for late reporting in treatment centres need to be explored, especially 
among male HIV-infected patients in Far-western Development Region, Nepal. 
f) Larger studies are needed to assess the determinants of mortality in male and female 
patients separately, and to examine whether the determinants effect is different between 
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11. APPENDICES  
 
Appendix 1:  
 
WHO Clinical Staging of HIV /AIDS for Adults and Adolescents, 2012 
 
a. Clinical Stage I 
- Asymptomatic    -   Persistent generalized lymphadenopathy 
b. Clinical Stage II 
- Unexplained moderate weight loss (<10% of presumed or measured body weight)a 
- Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media and pharyngitis) 
- Herpes zoster   -   Angular chelitis 
- Recurrent oral ulceration -   Papular pruritic eruptions 
- Seborrhoeic dermatitis  -   Fungal nail infections  
c. Clinical Stage IIIb 
- Unexplained severe weight loss (>10% of presumed or measured body weight)  
- Unexplained chronic diarrhea for longer than one month 
- Unexplained persistent fever (above 37.5°C intermittent or constant, for longer than 1 month) 
- Persistent oral candidiasis  -   Oral hairy leukoplakia 
- Pulmonary tuberculosis 
- Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, 
meningitis or bacteraemia) 
- Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
- Unexplained anaemia (<8 g/dl), neutropenia (<0.5 × 109 per litre) and/ or chronic 
thrombocytopenia (<50 × 109 per litre) 
d. Clinical Stage IVc 
- HIV wasting syndrome  -   Pneumocystis pneumonia 
- Recurrent severe bacterial pneumonia 
- Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month's duration 
or visceral at any site) 
- Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
- Extrapulmonary tuberculosis Kaposi sarcoma 
- Cytomegalovirus infection (retinitis or infection of other organs) Central nervous system 
toxoplasmosis 
- HIV encephalopathy  -   Extrapulmonary cryptococcosis including meningitis 
- Disseminated non-tuberculous mycobacterial infection 
- Progressive multifocal leukoencephalopathy 
- Chronic cryptosporidiosis -   Chronic isosporiasis 
- Disseminated mycosis (extrapulmonary histoplasmosis or coccidiomycosis) 
- Recurrent septicaemia (including non-typhoidal Salmonella) 
- Lymphoma (cerebral or B-cell non-Hodgkins) 
- Invasive cervical carcinomas -   Atypical disseminated leishmaniasis 




 Assessment of body weight in pregnant woman needs to consider the expected weight gain of pregnancy.  
b 
Unexplained refers to where the condition is not explained by other causes. 
c 
Some additional specific conditions 




Appendix 2:  
Data collection form (questionnaire) 
Participant number: ……….. 
ART centre/sub-centre (Name): …………………….. 
Place of ART centre/sub-centre (District): …………………….. 
 
1. Date of ART start: …………….. 
2. Death: Yes ………. No ………….. If Yes, Date of Death: …………………. 
3. Loss to follow-up: Yes ……......... No …….……. 
If Yes, Date of loss to follow-up (drop out): …………………. 
4. Transferred out: Yes ………… No …………… 
If Yes, Date of Transferred out: …………………………. 
Baseline Characteristics: 
1. Age: …………….. 
2. Sex: a) male……. b) female………. 
3. Education: a) illiterate………… b) literate ………… 
Baseline Clinical Characteristics: 
1. Active TB during treatment: a) yes…….. b) no……… 
2. Baseline performance scale ……………….. 
3. Baseline Bodyweight: ………..Kg 
4. WHO clinical stage: …………….. 
5. Baseline CD4 count: ……………….cells/mm3 
6. ART regimen: …………………. 
Follow-up information: 
1. Treatment regimen: ……………………………………………………………………… 
If changed, specify the name……………………………………………….. 
       specify the reason ………………………………………………………… 
2. Drug allergy: a) yes …………..b) no …………. 
If yes, specify the type of allergy …………………… 
3. Bodyweight:   
a) 6 months……………… Kg 
b) 12 months ……………Kg 
c) 24 months …………….Kg  
4. CD4 count:  
a) 6 months……………… cells/mm3 
b) 12 months …………… cells/mm3 
c) 24 months …………….cells/mm3 
5. Performance scale: 
a) 6 months……………… 
b) 12 months ……………  
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Appendix 12:  
Letter of permission from Baitadi District Hospital, Baitadi District 
 
